Pathogenesis of Osteopenia/osteoporosis Induced by Highly Active Anti-retroviral Therapy for AIDS

Overview

Journal Ann N Y Acad Sci

Specialty Science

Date 2006 Jul 13

PMID 16831930

Citations 15

Authors

George Pan

Zhen Yang

Scott W Ballinger

Jay M McDonald

Affiliations

Soon will be listed here.

Abstract

The advent of highly active anti-retroviral therapy (HAART) has dramatically decreased the rate of AIDS-related mortality and significantly extended the life span of patients with AIDS. A variety of metabolic side effects are associated with these therapies, one of which is metabolic bone disease. A higher prevalence of osteopenia and osteoporosis in HIV-infected patients receiving anti-retroviral therapy than in patients not on therapy has now been reported in several studies. Several factors have been demonstrated to influence HIV-associated decreases in bone mineral density (BMD), including administration of nucleoside reverse transcriptase inhibitors (NRTIs). In this article, discussion will focus on the molecular pathogenesis and treatment of HAART-associated osteopenia and osteoporosis.

Citing Articles

Femoral Neck Fractures in HIV-Positive Patients: Analysis of 10 Years Short-Term Post-operative Complications.

Manzotti A, Larghi M, Schianchi A, Grassi M, Pullen C, Cerveri P Malays Orthop J. 2021; 15(3):65-70.

PMID: 34966497 PMC: 8667258. DOI: 10.5704/MOJ.2111.010.

Retrospective study of the success of dental implants placed in HIV-positive patients.

Rubinstein N, Jacobson Z, McCausland G, Dibart S Int J Implant Dent. 2019; 5(1):30.

PMID: 31396731 PMC: 6687790. DOI: 10.1186/s40729-019-0174-6.

Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected With HIV in Early Life.

Unsal A, Mattingly A, Jones S, Purdy J, Reynolds J, Kopp J J Clin Endocrinol Metab. 2017; 102(8):2896-2904.

PMID: 28531309 PMC: 5546869. DOI: 10.1210/jc.2017-00197.

Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Mirza F, Canalis E Eur J Endocrinol. 2015; 173(3):R131-51.

PMID: 25971649 PMC: 4534332. DOI: 10.1530/EJE-15-0118.

HIV infection and osteoporosis.

Compston J Bonekey Rep. 2015; 4:636.

PMID: 25709813 PMC: 4325555. DOI: 10.1038/bonekey.2015.3.

References

Luger N, Honore P, Sabino M, Schwei M, Rogers S, Mach D . Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res. 2001; 61(10):4038-47. View

Chiocchia G, Bessis N, Batteux F, Muller S, Huang S, Boissier M . High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol. 1997; 158(11):5501-6. View

Anderson D, Maraskovsky E, Billingsley W, Dougall W, Tometsko M, Roux E . A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997; 390(6656):175-9. DOI: 10.1038/36593. View

Wong T, So M . Primary human immunodeficiency virus infection: heightened awareness needed. Hong Kong Med J. 2001; 7(2):205-8. View

Eiken P, Nielsen S, Kolthoff N . Effects on bone mass after eight years of hormonal replacement therapy. Br J Obstet Gynaecol. 1997; 104(6):702-7. DOI: 10.1111/j.1471-0528.1997.tb11981.x. View

Fakruddin J, Laurence J . HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem. 2003; 278(48):48251-8. DOI: 10.1074/jbc.M304676200. View

Papadopulos-Eleopulos E, Turner V, Papadimitriou J, Causer D, Alphonso H, Miller T . A critical analysis of the pharmacology of AZT and its use in AIDS. Curr Med Res Opin. 2001; 15 Suppl 1:S1-45. DOI: 10.1185/03007999909114096. View

Cossarizza A, Moyle G . Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS. 2004; 18(2):137-51. DOI: 10.1097/00002030-200401230-00002. View

Tai V, Schambelan M, Algren H, Shayevich C, Mulligan K . Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. Clin Infect Dis. 2002; 35(10):1258-62. DOI: 10.1086/343051. View

10.

Aukrust P, Haug C, Ueland T, Lien E, Muller F, Espevik T . Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999; 84(1):145-50. DOI: 10.1210/jcem.84.1.5417. View

11.

Pan G, Wu X, McKenna M, Feng X, Nagy T, McDonald J . AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses. 2004; 20(6):608-20. DOI: 10.1089/0889222041217482. View

12.

Tebas P, Powderly W, Claxton S, Marin D, Tantisiriwat W, Teitelbaum S . Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000; 14(4):F63-7. PMC: 3170993. DOI: 10.1097/00002030-200003100-00005. View

13.

Wei S, Kitaura H, Zhou P, Ross F, Teitelbaum S . IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 2005; 115(2):282-90. PMC: 544608. DOI: 10.1172/JCI23394. View

14.

Mondy K, Tebas P . Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003; 36(Suppl 2):S101-5. DOI: 10.1086/367566. View

15.

Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P . Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol. 1997; 158(11):5507-13. View

16.

Belmonte M, Garcia-Portales R, Domenech I, Fernandez-Nebro A, Camps M, de Ramon E . Avascular necrosis of bone in human immunodeficiency virus infection and antiphospholipid antibodies. J Rheumatol. 1993; 20(8):1425-8. View

17.

Biswas D, Mhashilkar A, Ewaniuk D, Pezza J, Oh L, Kannangara G . Inhibition of HIV-1 replication by combination of a novel inhibitor of TNF-alpha with AZT. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 18(5):426-34. DOI: 10.1097/00042560-199808150-00003. View

18.

Serrano S, Marinoso M, Soriano J, Rubies-Prat J, Aubia J, Coll J . Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone. 1995; 16(2):185-91. DOI: 10.1016/8756-3282(94)00028-x. View

19.

Oyajobi B, Anderson D, Traianedes K, Williams P, Yoneda T, Mundy G . Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 2001; 61(6):2572-8. View

20.

Amiel C, Ostertag A, Slama L, Baudoin C, Nguyen T, Lajeunie E . BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res. 2004; 19(3):402-9. DOI: 10.1359/JBMR.0301246. View